From drug discovery research . . .

... to the clinic.
We can help you navigate your path to more productive R & D.

Haberman Associates

Consulting for effective life science R&D and partnering

Haberman Associates is a Boston-based consulting firm, founded in 1993, that specializes in science and technology strategy for biotechnology, pharmaceutical, and other life science companies.

We assist your company to achieve its business goals in new product development and commercialization. Our focus is on effective R&D, business development, and partnering.

Clients have used our consulting services to help them:

  • discover and develop new drugs, diagnostics, and research products
  • improve their drug pipelines
  • identify and evaluate potential partners
  • develop new applications for their technologies
  • penetrate new markets

For additional information about how we can assist your company, please see “About Haberman Associates“.

For an initial discussion of your company’s needs, or if you have any questions about our firm, please contact us.

Haberman Associates is a member of the Boston-based Biopharmaceutical Consortium and an Affiliate of the North Carolina-based consulting consortium Innovalyst. Working with our consortium partners, we can form project teams of senior consultants to handle both small and large consulting engagements, for companies of all sizes worldwide.

Haberman Associates in the news …

Oct. 11, 2016: Dr. Haberman quoted in an article on gene therapy for hemophilia in Nature Biotechnology. Read more…

Nov. 6, 2015: Gene Therapy: Moving Toward Commercialization published by Cambridge Healthtech Institute. Read more…

Sept. 9, 2014: Cancer Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies published by Cambridge Healthtech Institute. Read more…

Mar. 11, 2013: Dr. Haberman quoted in article on the cystic fibrosis drug market in The Pink Sheet. Read more…

November 19, 2012:  Dr. Haberman quoted in an article on Agios Pharmaceuticals in Chemical & Engineering News. Read more…